| Views | |
|---|---|
| Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 263 |
| May 2025 | June 2025 | July 2025 | August 2025 | September 2025 | October 2025 | November 2025 | |
|---|---|---|---|---|---|---|---|
| Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 1 | 7 | 2 | 3 | 12 | 31 | 1 |
| Views | |
|---|---|
| 2021_Frost_etal.pdf | 277 |
